Palisade Bio (PALI) Capital Expenditures (2010 - 2022)
Palisade Bio (PALI) posted quarterly Capital Expenditures of $10000.0 for Q4 2022, up 900.0% quarter-over-quarter from $1000.0 in Q4 2020.
Powered by 
Analysis
Palisade Bio (PALI) Capital Expenditures (2010 - 2022) Analysis & Trends
Palisade Bio (PALI) has reported Capital Expenditures for 12 consecutive years, with $10000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Capital Expenditures changed N/A year-over-year to $10000.0; the TTM figure through Sep 2024 stood at $10000.0 (changed 0.0% YoY), while the FY2023 annual figure was $4000.0, down 60.0% from the prior year.
- Capital Expenditures climbed to $10000.0 in Q4 2022 per PALI's latest filing, from $1000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $10000.0 in Q4 2022 and bottomed at -$22381.0 in Q2 2019.
- Historically, Capital Expenditures has averaged -$4256.0 across 4 years, with a median of -$1000.0 in 2020.
- Annual changes were most pronounced in 2018 — Capital Expenditures surged 2415.72% — and 2019, when it sank 578.12%.
- Palisade Bio's Capital Expenditures stood at -$2286.0 in 2018, then tumbled by 879.05% to -$22381.0 in 2019, then surged by 104.47% to $1000.0 in 2020, then surged by 900.0% to $10000.0 in 2022.
- Business Quant data shows PALI's Capital Expenditures at $10000.0 in Q4 2022, $1000.0 in Q4 2020, and -$1000.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 10,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Jun 30, 2019 | -22,381.00 |
| Mar 31, 2019 | -19,125.00 |
| Dec 31, 2018 | -2,286.00 |
| Mar 31, 2018 | 4,000.00 |
| Dec 31, 2017 | 408.00 |
| Sep 30, 2017 | 1,319.00 |
| Jun 30, 2017 | 9,515.00 |
| Mar 31, 2017 | 159.00 |
| Jun 30, 2016 | 83,490.00 |
| Mar 31, 2016 | 14,598.00 |
| Dec 31, 2015 | 48,059.00 |
| Sep 30, 2015 | 32,194.00 |
| Jun 30, 2015 | 79,967.00 |
| Mar 31, 2015 | 16,052.00 |
| Dec 31, 2014 | 35,722.00 |
| Sep 30, 2014 | 27,080.00 |
| Jun 30, 2014 | 34,004.00 |